Alexion Pharmaceuticals (ALXN) Given New $136.00 Price Target at Stifel Nicolaus
Alexion Pharmaceuticals (NASDAQ:ALXN) had its price target raised by Stifel Nicolaus from $130.00 to $136.00 in a research note published on Tuesday morning. Stifel Nicolaus currently has a hold rating on the biopharmaceutical company’s stock.
Several other brokerages have also issued reports on ALXN. BidaskClub raised Alexion Pharmaceuticals from a sell rating to a hold rating in a report on Saturday, June 23rd. Zacks Investment Research lowered Alexion Pharmaceuticals from a buy rating to a hold rating in a report on Monday, August 13th. Credit Suisse Group raised their price objective on Alexion Pharmaceuticals from $149.00 to $154.00 and gave the stock an outperform rating in a report on Tuesday, June 5th. ValuEngine lowered Alexion Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday, June 26th. Finally, Evercore ISI reaffirmed an outperform rating and set a $158.00 price objective on shares of Alexion Pharmaceuticals in a report on Thursday, July 26th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and fifteen have issued a buy rating to the stock. Alexion Pharmaceuticals has a consensus rating of Buy and an average target price of $159.50.
Shares of ALXN stock opened at $138.27 on Tuesday. The stock has a market cap of $30.22 billion, a price-to-earnings ratio of 22.72, a PEG ratio of 1.28 and a beta of 0.84. Alexion Pharmaceuticals has a 1 year low of $102.10 and a 1 year high of $144.91. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.27 and a current ratio of 2.72.
In related news, CFO Paul J. Clancy sold 5,241 shares of the firm’s stock in a transaction dated Tuesday, July 10th. The stock was sold at an average price of $131.11, for a total transaction of $687,147.51. Following the transaction, the chief financial officer now owns 93,309 shares of the company’s stock, valued at $12,233,742.99. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 4.35% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ALXN. Point72 Asia Hong Kong Ltd grew its holdings in shares of Alexion Pharmaceuticals by 3,156.7% during the first quarter. Point72 Asia Hong Kong Ltd now owns 977 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 947 shares during the last quarter. Advisory Services Network LLC grew its holdings in shares of Alexion Pharmaceuticals by 145.3% during the second quarter. Advisory Services Network LLC now owns 883 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 523 shares during the last quarter. Berson & Corrado Investment Advisors LLC purchased a new position in shares of Alexion Pharmaceuticals during the second quarter worth about $205,000. Financial Gravity Wealth Inc. purchased a new position in shares of Alexion Pharmaceuticals during the first quarter worth about $211,000. Finally, Essex Financial Services Inc. purchased a new position in shares of Alexion Pharmaceuticals during the second quarter worth about $232,000. 93.02% of the stock is currently owned by hedge funds and other institutional investors.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
See Also: Stop Order Uses For Individual Investors
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.